Basic Information
MorphoSys AG, founded on March 3, 1998, is a late-stage biopharmaceutical company dedicated to developing innovative and differentiated therapies for patients with serious diseases. Based on its proprietary technology platforms and leading position in the fields of therapeutic antibody discovery, generation, and engineering, the company, together with its partners, is involved in the development of more than 100 therapeutic products. The company currently has 28 product candidates in clinical development, including its most advanced proprietary product candidate, MOR208, for the treatment of relapsed or refractory diffuse large B-cell lymphoma.